{"id":9844,"date":"2021-05-17T10:16:03","date_gmt":"2021-05-17T17:16:03","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9844"},"modified":"2021-05-18T10:16:49","modified_gmt":"2021-05-18T17:16:49","slug":"the-spike-proteins-of-sars-cov-2-b-1-617-and-b-1-618-variants-identified-in-india-provide-partial-resistance-to-vaccine-elicited-and-therapeutic-monoclonal-antibodies","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/the-spike-proteins-of-sars-cov-2-b-1-617-and-b-1-618-variants-identified-in-india-provide-partial-resistance-to-vaccine-elicited-and-therapeutic-monoclonal-antibodies\/","title":{"rendered":"The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> The SARS-CoV-2 <\/span><span style=\"font-weight: 400\">B.1.617 and B.1.618 strains currently circulating in India were found to have specific spike protein mutations (B.1.617 = L452R\/E484Q\/D614G\/P681R, B.1.618 = \u0394145-146\/E484K\/D614G) that were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies, and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be protective. A study generating pseudoviruses found that those with B.1.617 and B.1.618 spike proteins had an average of 3.9-fold and 2.7-fold <\/span><span style=\"font-weight: 400\">reductions<\/span><span style=\"font-weight: 400\"> in the <\/span><span style=\"font-weight: 400\">half maximal <\/span><span style=\"font-weight: 400\">inhibitory concentration for convalescent sera and antibodies from the Pfizer-BioNTech and Moderna vaccines, respectively, which the authors suggest could be due to the L452R, E484Q, and E484K mutations. Both variants also had some resistance to <\/span><span style=\"font-weight: 400\">the monoclonal antibodies made by Regeneron<\/span><span style=\"font-weight: 400\">.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Tada et al.\u00a0(May 16, 2021). The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies. Pre-print downloaded May 17 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.14.444076\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.14.444076<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] The SARS-CoV-2 B.1.617 and B.1.618 strains currently circulating in India were found to have specific spike protein mutations (B.1.617 = L452R\/E484Q\/D614G\/P681R, B.1.618 = \u0394145-146\/E484K\/D614G) that were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies, and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/the-spike-proteins-of-sars-cov-2-b-1-617-and-b-1-618-variants-identified-in-india-provide-partial-resistance-to-vaccine-elicited-and-therapeutic-monoclonal-antibodies\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142,159],"topic":[31],"class_list":["post-9844","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9844"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9844\/revisions"}],"predecessor-version":[{"id":9845,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9844\/revisions\/9845"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9844"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}